Pulse Biosciences (NASDAQ:PLSE) Receives Downgrade to Sell Rating

Pulse Biosciences (NASDAQ:PLSE) was recently downgraded to a "sell" rating by analysts at StockNews.com, as stated in a report issued on Monday.

Stock Performance of Pulse Biosciences

On the same day, Pulse Biosciences' stock price decreased by $0.51, closing at $16.09. The trading volume for the day reached 459,987 shares, significantly higher than the average volume of 198,258 shares. The company has seen a fifty-day simple moving average at $18.78 and a two-hundred-day simple moving average at $18.15. Over the past year, Pulse Biosciences has recorded a low of $6.60 and a high of $25.00.

Institutional Trading Activity

Recently, various hedge funds have adjusted their positions in Pulse Biosciences. Invesco Ltd. made a significant adjustment by increasing its stake in the company by an impressive 1,956.7% during the fourth quarter, now holding 214,490 shares valued at approximately $3,734,000 after acquiring 204,061 additional shares. Vanguard Group Inc. also expanded its holdings by 15.1% in the same quarter, bringing its total to 1,146,339 shares valued at $19,958,000 following the acquisition of 150,506 shares. Additionally, Charles Schwab Investment Management Inc. raised its position by 193.0% during the third quarter, now owning 148,114 shares valued at $2,598,000 after purchasing another 97,565 shares. Moreover, State Street Corp increased its stake in Pulse Biosciences by 17.8% in the third quarter, bringing its total to 461,333 shares with a worth of $8,092,000 after buying an additional 69,696 shares. Lastly, Panoramic Capital LLC acquired a new stake in the fourth quarter valued at approximately $846,000. It appears that 76.95% of Pulse Biosciences’ stock is held by institutional investors.

Overview of Pulse Biosciences

Pulse Biosciences, Inc. operates as an innovative bioelectric medicine company. The firm is known for its CellFX System, which is a software-enabled, tunable platform that delivers electrical energy pulses in nanosecond durations aimed at selectively treating targeted cells while sparing adjacent, non-cellular tissue through its unique Nano-Pulse Stimulation technology.

Investment Insights

Investors considering Pulse Biosciences may want to re-evaluate their positions in light of the recent downgrade. Research analysts have noted that there are alternative stocks currently deemed more favorable, and Pulse Biosciences has not been featured among the preferred selections of top analysts.

Conclusion

Given the recent downgrade and current stock performance, potential investors should conduct further research and consider these findings seriously when assessing their options in the market.

Pulse, Biosciences, Stock